Central South Univ. ASS1 compound 10f

Central South Univ. ASS1 compound 10f: sourced facts only. name: "Among these, compound 10f demonstrated substantially enhanced ASS1 activation and superior cytotoxicity against various cancer cells compared to SPA." [PMID:41673957]; target: "Among these, compound 10f demonstrated substantially enhanced ASS1 activation and superior cytotoxicity against various cancer cells compared to SPA." [PMID:41673957]; developer: "Xiangya School of Pharmaceutical Sciences, Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China." [PMID:41673957]; stage: "In vivo studies confirmed that 10f possesses significantly improved antitriple-negative breast cancer efficacy compared to SPA, highlighting its substantial therapeutic potential." [PMID:41673957]